Table 3 Summary of grade 2 and greater toxicities
From: Phase II trial of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
Adverse events (%) | Toxicity grade (N = 80) | |||
|---|---|---|---|---|
Grade 2 | Grade 3 | Grade 4 | All | |
Neutropenia | 21 (26.2) | 6 (7.5) | 7 (8.8) | 34 (42.5) |
Sensory Neuropathy | 12 (15) | 2 (2.5) | 1 (1.2) | 15 (18.8) |
Fatigue | 5 (6.2) | 0 | 0 | 5 (6.2) |
Arthralgia / Myalgia | 4 (5) | 0 | 0 | 4 (5) |
Diarrhea | 1 (1.2) | 3 (3.8) | 0 | 4 (5) |
Leukopenia | 4 (5) | 0 | 1 (1.2) | 5 (6.2) |
Elevated alanine aminotransferase | 2 (2.5) | 0 | 0 | 2 (2.5) |
Infection | 2 (2.5) | 0 | 0 | 2 (2.5) |
Rash | 2 (2.5) | 0 | 0 | 2 (2.5) |